{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T14:27:53Z","timestamp":1685370473917},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T00:00:00Z","timestamp":1519948800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amgen Romania"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["memo"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12254-018-0390-4","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T12:37:33Z","timestamp":1519994253000},"page":"144-151","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["APPLY: A\u00a0prospective observational study of clinical practice patterns of darbepoetin alfa use in patients with chemotherapy-induced anemia in Romania"],"prefix":"10.1007","volume":"11","author":[{"given":"Nicoleta Mariana","family":"Berbec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana Lucia","family":"Stanculeanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoleta Sorina","family":"Badelita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Vasilica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorel Ionel","family":"Popovici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Colita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Neacsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandru","family":"Iordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,2]]},"reference":[{"issue":"19","key":"390_CR1","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","volume":"91","author":"JE Groopman","year":"1999","unstructured":"Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J\u00a0Natl Cancer Inst. 1999;91(19):1616\u201334.","journal-title":"J Natl Cancer Inst"},{"issue":"3 Suppl 7","key":"390_CR2","first-page":"2","volume":"25","author":"H Ludwig","year":"1998","unstructured":"Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol. 1998;25(3 Suppl 7):2\u20136.","journal-title":"Semin Oncol"},{"issue":"2","key":"390_CR3","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cncr.10245","volume":"94","author":"D Cella","year":"2002","unstructured":"Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94(2):528\u201338.","journal-title":"Cancer"},{"issue":"Suppl 3","key":"390_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1634\/theoncologist.13-S3-33","volume":"13","author":"MS Aapro","year":"2008","unstructured":"Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist. 2008;13(Suppl 3):33\u20136.","journal-title":"Oncologist"},{"issue":"Suppl 5","key":"390_CR5","doi-asserted-by":"publisher","first-page":"v244","DOI":"10.1093\/annonc\/mdq202","volume":"21","author":"D Schrijvers","year":"2010","unstructured":"Schrijvers D, De Samblanx H, Roila F, Group EGW. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO clinical practice guidelines for use. Ann Oncol. 2010;21(Suppl 5):v244\u2013v7.","journal-title":"Ann Oncol"},{"key":"390_CR6","volume-title":"Aranesp summary of product characteristics. European Medicines Agency","author":"European Medicines Agency","year":"2015","unstructured":"European Medicines Agency. Aranesp summary of product characteristics. European Medicines Agency. 2015. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000332\/human_med_000651.jsp&mid=WC0b01ac058001d124 . Accessed 27 Mar 2017."},{"key":"390_CR7","volume-title":"Romanian-protocol 2008, Health Minister Order 1301\/500 from 11 july 2008","author":"Romanian Health Ministry","year":"2008","unstructured":"Romanian Health Ministry. Romanian-protocol 2008, Health Minister Order 1301\/500 from 11 july 2008. 2008."},{"issue":"1","key":"390_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1179\/1607845412Y.0000000033","volume":"18","author":"R Pettengell","year":"2013","unstructured":"Pettengell R, Silvestre AS, Schwenkglenks M, Rossi FG, Duehrsen U, Verhoef G, Lugtenburg PJ, Wheeler T, Pujol B, Haioun C. Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (\u00b1R) CHOP. Hematology. 2013;18(1):26\u20139.","journal-title":"Hematology"},{"key":"390_CR9","doi-asserted-by":"crossref","unstructured":"Boguradzki P, Bo\u00e9r K, Cipkov\u00e1 A, Wojciechowska-Lampka E, Sch\u00fctzov\u00e1 M, Ocvirk J, T\u00f3th E. Oncology Pro. A prospective data audit of the management of chemotherapy-induced anemia with darbepoetin alfa 6 the APRIORI study. 2012. http:\/\/oncologypro.esmo.org\/Meeting-Resources\/ESMO-2012\/A-prospective-data-audit-of-the-management-of-chemotherapy-induced-anemia-with-darbepoetin-alfa-6-the-APRIORI-study . Accessed 27 Oct 2016.","DOI":"10.1016\/S0923-7534(20)34106-5"},{"issue":"5","key":"390_CR10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1185\/03007995.2011.562493","volume":"27","author":"S Belle Van","year":"2011","unstructured":"Van Belle S, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B. Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy\u2014data from the CHOICE study. Curr Med Res Opin. 2011;27(5):987\u201394.","journal-title":"Curr Med Res Opin"},{"issue":"S8","key":"390_CR11","first-page":"viii","volume":"21","author":"S Belle Van","year":"2010","unstructured":"Van Belle S, Urbanski K, Orfeuvre H, Foucher P, Wheeler T, Pujol B. Darbepoetin alfa dosing weekly and every three weeks in cancer patients with chemotherapy-induced anaemia\u2014efficacy data from the CHOICE study. Ann Oncol. 2010;21(S8):viii\u2013386.","journal-title":"Ann Oncol"},{"issue":"3","key":"390_CR12","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1007\/s12032-011-0103-x","volume":"29","author":"JL Canon","year":"2012","unstructured":"Canon JL, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Legg J, Pujol B, Bridges K. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g\/dL versus 9 to <10 g\/dL versus \u2265 10 g\/dL: an exploratory analysis of a phase 3 trial. Med Oncol. 2012;29(3):2291\u20139.","journal-title":"Med Oncol"},{"issue":"2","key":"390_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00520-012-1538-0","volume":"21","author":"M Deger","year":"2013","unstructured":"Deger M, Eisterer W, Kutikova L, Salek S. Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. Support Care Cancer. 2013;21(2):485\u201393.","journal-title":"Support Care Cancer"}],"container-title":["memo - Magazine of European Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12254-018-0390-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12254-018-0390-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12254-018-0390-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T22:48:23Z","timestamp":1603925303000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12254-018-0390-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["390"],"URL":"https:\/\/doi.org\/10.1007\/s12254-018-0390-4","relation":{},"ISSN":["1865-5041","1865-5076"],"issn-type":[{"value":"1865-5041","type":"print"},{"value":"1865-5076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,2]]},"assertion":[{"value":"13 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.M.\u00a0Berbec has received consulting fees from Amgen. D.L.\u00a0Stanculeanu has received consulting fees from Amgen, Janssen, and Roche and is a\u00a0member of the speakers bureau of Amgen, Roche, Merck, Novartis, Astellas, Janssen, Bristol-Myers Squibb, and Astra-Zeneca. N.S.\u00a0Badelita received consulting fees from Amgen and is a\u00a0member of the speakers bureau of Amgen. A.\u00a0Colita received speakers fees from Amgen. C.\u00a0Neacsu and A.\u00a0Iordan are employees of Amgen and hold Amgen stock. M.\u00a0Vasilica and D.I.\u00a0Popovici declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}